ACRES COMMERCIAL REALTY CORP ACR 深 滬
已收盤 12-12 16:00:00 美东时间
23.71
+0.010
+0.04%
華盛通- 最 高23.99
- 今 開23.85
- 成交量 3.70万股
- 最 低 23.4401
- 昨 收 23.70
- 總市值 1.76亿
- 52周最高 24.17
- 市盈率 靜 20.60
- 換手率 0.50%
- 52周最低 15.35
- 委 比 33.33%
- 總股本 742.63万
- 歷史最高 37.53
- 量 比 0.72
- 振 幅 2.32%
- 歷史最低 2.85
- 每 手 1
- 風險率 1.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
AnaptysBio Announces Late-Breaking Data From Global 424-Patient Phase 2b Trial Of Rosnilimab In Rheumatoid Arthritis At ACR Convergence 2025
New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including
10-29 21:19
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
百时美施贵宝公布两项最新研究数据：氘可来昔替尼可有效治疗银屑病关节炎及系统性红斑狼疮
近日，百时美施贵宝公布了关键性III期POETYK PsA-1 试验的最新数据，进一步证实了氘可来昔替尼在未接受过生物制剂类改善病情抗风湿药物（bDMARD）治...
10-29 16:53
Vardhman Acrylics Publishes Financial Results for September 2025
An announcement from Vardhman Acrylics Ltd. ( ($IN:VARDHACRLC) ) is now availab...
10-23 16:53
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gain...
10-21 20:16
小马智行通过上市聆讯：上半年营收3543万美元 红杉与丰田是股东
雷递网 雷建平 10月17日 自动驾驶企业Pony.ai（小马智行）今天通过港交所上市聆讯，即将踏入港股市场。 小马智行是2024年11月底在美国纳斯达克挂牌上...
10-17 20:28
AnaptysBio Says Complete Data From Phase 2b Trial Of Rosnilimab, Pathogenic T Cell Depleter, In RA, Accepted For Late-Breaking Oral Presentation At ACR Convergence 2025
AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T
10-13 21:18
